Big news: our prices just got a lot lower. Shop now|New here? Get up to $200 in welcome perks, valid for 14 days. Claim offer now
US shipping INCLUDED on orders above $200
Research Insights

All content and product details on this site are for educational purposes only. Products are for in-vitro studies (performed outside the body) and not FDA-approved for medical use. Any introduction into humans or animals is prohibited by law.

Sermorelin Peptide: Growth Hormone Secretion Research

Nabiha Khalid
October 27, 2026
Sermorelin Peptide: Growth Hormone Secretion Research

Brief Overview/Summary

Explore research on Sermorelin peptide, its role in growth hormone secretion and pituitary function through scientific studies

Sermorelin, a synthetic peptide and growth hormone-releasing hormone (GHRH) analogue, has been studied for its effect on growth hormone (GH) secretion from the pituitary gland. It is a 29-amino-acid analogue of human GHRH and has been described as the shortest synthetic peptide with the full biological activity of GHRH [1].

This particular peptide corresponds to the N-terminal 1–29 region of natural GHRH. Structure–activity studies showed that this fragment, GHRH(1–29)NH2, retains GH-releasing activity on rat anterior pituitary cells [2]. GHRH itself was characterised in 1982 from human pancreatic tumours, and the native and synthetic peptides were shown to be potent and specific stimulators of GH release from cultured rat pituitary cells [3][4].

Sermorelin acts on GHRH receptors on the pituitary gland. The GHRH receptor is a G protein-coupled receptor that is expressed predominantly in the anterior pituitary, the major target of GHRH action [5]. Its activation leads to the release of GH from pituitary somatotroph cells [6].

These functions of the pituitary gland are particularly important for its research relevance, because they involve the release of the pituitary's own GH under its normal regulatory controls, including inhibition by somatostatin [4][7]. Research on sermorelin has therefore focused on the regulation of GH secretion and on the GH/IGF-1 axis [6][8].

Sermorelin has been studied as a targeted tool for stimulating the pituitary gland's GHRH receptors. Because of its effect on GH release, it has been a subject of endocrine research.

Mechanism of Action of Sermorelin Peptide

A well-orchestrated physiological cascade is what allows Sermorelin to work. By binding to GHRH receptors on pituitary somatotroph cells, this synthetic peptide activates intracellular signalling; when the cloned GHRH receptor was expressed in cultured cells, GHRH binding stimulated intracellular cAMP production [5]. This signalling leads to the release of GH [6].

As a result of the specificity of this receptor binding, sermorelin mimics the effects of endogenous GHRH. In primary cultures of rat pituitary cells, GHRH peptides were highly specific for GH release, with no demonstrable effect on the secretion of other pituitary hormones, and somatostatin inhibited the GH release they produced [4].

GH secretion is pulsatile. In rats, the GH response to GHRH peptides varied markedly with the time of exposure within the ultradian GH rhythm, and the weak responses seen during trough periods were due to antagonism by endogenous somatostatin [7].

An increase in the release of GH from the pituitary gland stimulates the production of insulin-like growth factor-1 (IGF-1). Circulating IGF-1 is predominantly derived from the liver, while many tissues also produce IGF-1 that acts locally, and GH and IGF-1 have both related and independent roles in growth [8].

Sermorelin's position in this cascade, acting at the pituitary GHRH receptor upstream of GH and IGF-1, makes it a useful instrument in endocrine research [6].

Research Evidence of Sermorelin Peptide

Research on the GHRH fragment that sermorelin corresponds to began with structure–activity work. When C-terminally shortened analogues of human GHRH were synthesised and tested on rat anterior pituitary cells in culture, the fragments GHRH(1–31)NH2, (1–30)NH2 and (1–29)NH2 kept about half of the potency of the full hormone; further shortening produced fragments with very low potency, and the minimal biologically active core was defined as residues 3–21 [2].

According to the findings of these experiments, the 1–29 fragment is the shortest GHRH sequence that retains substantial GH-releasing potency, which is the basis for the design of sermorelin [2][1].

Studies of the GHRH receptor have further characterised sermorelin's target. The receptor was cloned from the rat pituitary, and its human homologue bound GHRH with high affinity and specificity [5]. In the dwarf little mouse, a single mutation in the GHRH receptor is associated with a hypoplastic anterior pituitary, linking GHRH-receptor signalling to the growth of GH-producing cells [9].

In rats, the interaction between GHRH and somatostatin is central to the generation of the ultradian rhythm of GH secretion [7]. These findings have made GHRH analogues such as sermorelin a subject of continued research on the regulation of GH secretion.

Research Application of Sermorelin Peptide

The adaptability of sermorelin as a synthetic GHRH analogue is attracting attention in the field of endocrine research, particularly for studies of pituitary somatotroph function and the regulation of GH secretion [6][5]. Endocrine investigations study the influence that GHRH-receptor agonists have on pituitary function by measuring the production of GH and the downstream IGF-1 response [6][8].

These studies provide insights into the peptide's effects on the GH axis, supporting its classification among hormone research peptides in modern endocrine research. Comparative research examines GHRH analogues alongside other GH-releasing compounds that act through different receptors [6].

Primary pituitary cell cultures, cells expressing the cloned GHRH receptor, genetic mouse models and measurement of GH secretion profiles in rats are among the research methodologies used to evaluate GHRH-receptor signalling [4][5][9][7]. The use of these methodologies helps ensure that the data collected on the effects of the peptide are accurate.

The synthetic nature of the peptide, together with its targeted action at the GHRH receptor, makes it a useful tool for the advancement of endocrine research.

Future Perspective

Sermorelin is a synthetic peptide that has been studied for its effect on GH release. Ongoing studies of GHRH and its receptor continue to inform endocrine research, including how GHRH-receptor signalling regulates the growth and function of somatotroph cells [5][9].

Open questions include how GHRH-receptor signalling interacts with somatostatin in shaping GH pulsatility, and how circulating and locally produced IGF-1 divide their roles downstream of GH [7][8].

Research that is now being conducted will further characterise the function of GHRH analogues such as sermorelin in studies of the GH axis.

References

  1. Prakash, A., & Goa, K. L. (1999). Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs, 12(2), 139-157. https://doi.org/10.2165/00063030-199912020-00007

  2. Ling, N., Baird, A., Wehrenberg, W. B., Ueno, N., Munegumi, T., & Brazeau, P. (1984). Synthesis and in vitro bioactivity of C-terminal deleted analogs of human growth hormone-releasing factor. Biochemical and Biophysical Research Communications, 123(2), 854-861. https://doi.org/10.1016/0006-291x(84)90309-7

  3. Rivier, J., Spiess, J., Thorner, M., & Vale, W. (1982). Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature, 300(5889), 276-278. https://doi.org/10.1038/300276a0

  4. Brazeau, P., Ling, N., Böhlen, P., Esch, F., Ying, S. Y., & Guillemin, R. (1982). Growth hormone releasing factor, somatocrinin, releases pituitary growth hormone in vitro. Proceedings of the National Academy of Sciences of the USA, 79(24), 7909-7913. https://doi.org/10.1073/pnas.79.24.7909

  5. Mayo, K. E. (1992). Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Molecular Endocrinology, 6(10), 1734-1744. https://doi.org/10.1210/mend.6.10.1333056

  6. Frohman, L. A., & Jansson, J. O. (1986). Growth hormone-releasing hormone. Endocrine Reviews, 7(3), 223-253. https://doi.org/10.1210/edrv-7-3-223

  7. Tannenbaum, G. S., & Ling, N. (1984). The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion. Endocrinology, 115(5), 1952-1957. https://doi.org/10.1210/endo-115-5-1952

  8. Butler, A. A., & Le Roith, D. (2001). Control of growth by the somatropic axis: growth hormone and the insulin-like growth factors have related and independent roles. Annual Review of Physiology, 63, 141-164. https://doi.org/10.1146/annurev.physiol.63.1.141

  9. Lin, S. C., Lin, C. R., Gukovsky, I., Lusis, A. J., Sawchenko, P. E., & Rosenfeld, M. G. (1993). Molecular basis of the little mouse phenotype and implications for cell type-specific growth. Nature, 364(6434), 208-213. https://doi.org/10.1038/364208a0

Read more about peptides